Proteomics as a tool to investigate cell models for dopamine toxicity

Parkinsonism and Related Disorders

Volumn 14, Issue SUPPL.2, 2008, Pages

  Fasano, Mauro ^a   Alberio, Tiziana ^a   Colapinto, Monica ^a   Mila, Silvia ^a   Lopiano, Leonardo ^b  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Synuclein; Dopamine; Human neuroblastoma; Human T cell leukaemia; Parkinson's disease; Proteomics

Indexed keywords

ALPHA SYNUCLEIN; CATALASE; DJ 1 PROTEIN; DOPAMINE; DOPAMINE TRANSPORTER; HEAT SHOCK PROTEIN 70; LEVODOPA; REACTIVE OXYGEN METABOLITE;

ARTICLE; CD25+ T LYMPHOCYTE; CD4 CD8 RATIO; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEUKEMIA CELL LINE; LEWY BODY; MASS SPECTROMETRY; NEUROBLASTOMA CELL; NEUROTOXICITY; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEOMICS; SUBSTANTIA NIGRA;

ANIMALS; CELL LINE, TUMOR; DOPAMINE; HUMANS; NEUROBLASTOMA; NEUROTOXICITY SYNDROMES; PROTEOMICS;

EID: 47049121158     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2008.04.016     Document Type: Article

References (32)

1. Hanash S. Disease proteomics. Nature 422 (2003) 226-232
2. Tao W.A., and Aebersold R. Advances in quantitative proteomics via stable isotope tagging and mass spectrometry. Curr Opin Biotechnol 14 (2003) 110-118
3. Wasinger V.C., Cordwell S.J., Cerpa-Poljak A., Yan J.X., Gooley A.A., Wilkins M.R., et al. Progress with gene-product mapping of the mollicutes: Mycoplasma genitalium. Electrophoresis 16 (1995) 1090-1094
4. Lee M.P. Genome-wide analysis of epigenetics in cancer. Ann N Y Acad Sci 983 (2003) 101-109
5. Becker M., Schindler J., and Nothwang H.G. Neuroproteomics-the tasks lying ahead. Electrophoresis 27 (2006) 2819-2829
6. Sheta E.A., Appel S.H., and Goldknopf I.L. 2D gel blood serum biomarkers reveal differential clinical proteomics of the neurodegenerative diseases. Expert Rev Proteomics 3 (2006) 45-62
7. Basso M., Giraudo S., Corpillo D., Bergamasco B., Lopiano L., and Fasano M. Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 4 (2004) 3943-3952
8. Fasano M., Bergamasco B., and Lopiano L. The proteomic approach in Parkinson's disease. Proteomics Clin Appl 1 (2007) 1428-1435
9. Cookson M.R. Pathways to Parkinsonism. Neuron 37 (2003) 7-10
10. Eriksen J.L., Wszolek Z., and Petrucelli L. Molecular pathogenesis of Parkinson's disease. Arch Neurol 62 (2005) 353-357
11. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2 (2001) 492-501
12. Hardy J., Cai H., Cookson M.R., Gwinn-Hardy K., and Singleton A. Genetics of Parkinson's disease and parkinsonism. Ann Neurol 60 (2006) 389-398
13. Maguire-Zeiss K.A., Short D.W., and Federoff H.J. Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?. Brain Res Mol Brain Res 134 (2005) 18-23
14. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 (2002) 256-259
15. Berg D., Youdim M.B., and Riederer P. Redox imbalance. Cell Tissue Res 318 (2004) 201-213
16. Fasano M., Bergamasco B., and Lopiano L. Modifications of the iron-neuromelanin system in Parkinson's disease. J Neurochem 96 (2006) 909-916
17. Zecca L., Gallorini M., Schünemann V., Trautwein A.X., Gerlach M., Riederer P., et al. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem 76 (2001) 1766-1773
18. Volles M.J., Lee S.J., Rochet J.C., Shtilerman M.D., Ding T.T., Kessler J.C., et al. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40 (2001) 7812-7819
19. Lashuel H.A., Petre B.M., Wall J., Simon M., Nowak R.J., Walz T., et al. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 322 (2002) 1089-1102
20. Colapinto M., Mila S., Giraudo S., Stefanazzi P., Molteni M., Rossetti C., et al. Alpha-synuclein protects SH-SY5Y cells from dopamine toxicity. Biochem Biophys Res Commun 349 (2006) 1294-1300
21. Choi H.S., Lee S.H., Kim S.Y., An J.J., Hwang S.I., Kim D.W., et al. Transduced Tat-alpha-synuclein protects against oxidative stress in vitro and in vivo. J Biochem Mol Biol 39 (2006) 253-262
22. Xu J., Zhong N., Wang H., Elias J.E., Kim C.Y., Woldman I., et al. The Parkinson's disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis. Hum Mol Genet 14 (2005) 1231-1241
23. Zhou W., and Freed C.R. DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity. J Biol Chem 280 (2005) 43150-43158
24. Mitsumoto A., and Nakagawa Y. DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin. Free Radic Res 35 (2001) 885-893
25. Fiszer U. Does Parkinson's disease have an immunological basis? The evidence and its therapeutic implications. BioDrugs 15 (2001) 351-355
26. McGeer P.L., and McGeer E.G. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 10 Suppl. 1 (2004) S3-S7
27. Cosentino M., Rasini E., Colombo C., Marino F., Blandini F., Ferrari M., et al. Dopaminergic modulation of oxidative stress and apoptosis in human peripheral blood lymphocytes: evidence for a D1-like receptor-dependent protective effect. Free Radic Biol Med 36 (2004) 1233-1240
28. Czlonkowska A., Kurkowska-Jastrzebska I., Czlonkowski A., Peter D., and Stefano G.B. Immune processes in the pathogenesis of Parkinson's disease-a potential role for microglia and nitric oxide. Med Sci Monit 8 (2002) RA165-RA177
29. Baba Y., Kuroiwa A., Uitti R.J., Wszolek Z.K., and Yamada T. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord 11 (2005) 493-498
30. Braak H., Ghebremedhin E., Rub U., Bratzke H., and Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318 (2004) 121-134
31. Barbanti P., Fabbrini G., Ricci A., Cerbo R., Bronzetti E., Caronti B., et al. Increased expression of dopamine receptors on lymphocytes in Parkinson's disease. Mov Disord 14 (1999) 764-771
32. Peirce M.J., Wait R., Begum S., Saklatvala J., and Cope A.P. Expression profiling of lymphocyte plasma membrane proteins. Mol Cell Proteomics 3 (2004) 56-65